VHOSPITAL.CLINIC · Drug Reference
Dapagliflozin is an SGLT-2 inhibitor that lowers blood glucose by promoting urinary glucose excretion, with additional benefits for heart and kidney protection.
This medication belongs to a class of agents used in specific medical conditions. Prescribing, dosing, and monitoring requirements vary by individual patient needs and concurrent medications.
Used as directed by a healthcare professional for the specific indication for which it has been prescribed.
Follow prescriber's instructions. Report any unusual symptoms. Do not stop without medical advice for most medications.
Empagliflozin
Empagliflozin is an SGLT-2 inhibitor that lowers blood glucose by promoting urinary glucose excretion, with additional benefits for heart and kidney protection.
Canagliflozin
Canagliflozin is an SGLT-2 inhibitor that lowers blood glucose by promoting urinary glucose excretion, with additional benefits for heart and kidney protection.
Ertugliflozin
Ertugliflozin is an SGLT-2 inhibitor that lowers blood glucose by promoting urinary glucose excretion, with additional benefits for heart and kidney protection.
Describe your symptoms and concerns and get a structured clinical assessment — possible causes, red flags, and recommended next steps.
Start Free AI Analysis →Medical Disclaimer: This drug reference is provided for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified health provider before starting, stopping, or changing any medication. Information reviewed by the vHospital Editorial Team · Sources: WHO, BNF, FDA prescribing information, UpToDate.